Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved transseptal mitral valve replacement
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The opening of our 1000th pharmacy in Karnataka marks an important step
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Subscribe To Our Newsletter & Stay Updated